Polyethyleneimine-based gene therapy by inhalation

Area of Science:

• Gene therapy
• Pulmonary medicine
• Nanotechnology

Background:

• Inhaled gene delivery offers advantages over invasive methods for treating lung diseases.
• Early aerosol gene delivery efforts using non-viral vectors faced challenges like nebulization forces and mucus barriers, limiting therapeutic effects.
• The cloning of the cystic fibrosis gene spurred interest in direct lung gene delivery.

Purpose of the Study:

• To evaluate the efficacy and safety of polyethyleneimine (PEI)-based gene delivery via aerosol for pulmonary applications.
• To overcome limitations of previous non-viral vector-based aerosol gene delivery systems.
• To explore the potential of inhaled gene therapy for treating lung disorders and for localized genetic immunization.

Main Methods:

• Development and testing of polyethyleneimine (PEI)-based formulations for aerosolized gene delivery.
• Assessment of transfection efficiency in airways and lung parenchyma.
• Evaluation of therapeutic responses in animal lung tumor models using PEI-complexed p53 and IL-12 genes.
• Analysis of toxicity and CpG immunostimulatory responses.

Main Results:

• PEI-based formulations demonstrated stability during nebulization and high transfection efficiency in airways (nearly 100%).
• Significant transfection was observed in the lung parenchyma.
• Therapeutic responses were achieved in animal lung tumor models.
• The delivery method exhibited low toxicity and minimal CpG immunostimulatory response.

Conclusions:

• Aerosolized PEI-based gene delivery is a promising strategy for treating pulmonary diseases, overcoming previous limitations.
• This approach has demonstrated therapeutic efficacy in preclinical lung cancer models.
• PEI-based inhaled gene therapy offers a potentially safe and effective platform for both disease treatment and localized genetic immunization.